Watch Ticker

Phio Pharmaceuticals Corp. Common Stock

Go to Phio Pharmaceuticals Corp. Common Stock Website

$2.35

0.00 (0.00%)

Live

Previous Close

$2.35

Day Range

$0 - $0

Previous Day Range

$2.31 - $2.47

Market Cap

$11.4 million USD

Day Vol.

Previous Day Vol.

162091

Currency

USD

Primary Exchange

Nasdaq

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Researchandmarkets.Com - Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033

The global retinoblastoma treatment market is projected to grow from $1.93 billion in 2023 to $2.03 billion in 2024, driven by factors like increased funding, cancer research, and technological advancements. The market is expected to reach $2.56 billion by 2028, growing at a CAGR of 5.9%.

Related tickers: JNJ, RHHBY, MRK, SNY, BMY, CELGr, NVS, PFE, GSK, TAK, LLY, TEVA, BAX, REGN, ALPMY, DSNKY, NPPNY, RCUS, PHIO.

Read Full Article

Phio Pharmaceuticals Corp. - Phio Pharmaceuticals Secures New Investor

--Fund invests in microcap equities --Fund invests in microcap equities

Related tickers: PHIO.

Read Full Article

Trending Tickers

Please sign in to view